shares of regeneron, up more than 25% in the past three months the pharma giant's ceo joins us live and a big downgrade for one of the big streaming stocks we will debate in call of the day. the investment committee is ready to go. the halftime report starts right now. >>> welcome. good to have you with us on this monday our investment committee, joe tear nova, josh brawn, steve wise brand and rob seechin. let's begin with the markets stocks at session highs. dow going for its close above 29,000 all this in what is a critical we can expectations are high. positioning is pull bullish. the numbers better live up don't you think? >> numbers i think will in certain instances have to meet high expectation i agree with that, scott but it seems we have rolled into 2020 and not much changed from 2019 you have been able to disburse allocations a little bit outside the u.s. chinese equities are off to a strong start the iem -- both of those performing well. we are in earnings season. i think the pressure is on financial institutions more than any other sector i agree with what jim cramer said las

to add exact sciences through 100 the other one is a little bit less of an urgent play which is regeneronthere's one consolidation, big breakout we've seen a lot of consolidation in re-generon. this is the weekly, if you get down to the daily chart, you have to wait for this one to break. if you just draw your trend line here, you're certainly going to find buy stops above the $400 region if you're been looking for biotech and regeneron through 400, that would be the time to add regeneron. >> thank you very much savita, what is your overall thinking about biotech or health care in particular health care is big and broad, biotech just one part of it. >> look, if you're going to buy and hold for the next decade, there is nothing wrong with health care and nothing wrong with biotech we're moving into this brave new world where there are going to be more grandparents than grandkids for the first time in human history. people are old today, like -- >> don't rub it in >> the percentage of the retiring population, not whatever happens out there today, remember, you have the hilton app. will the

both regeneron and veer have tested these druks successfully in the field they've shown great responsesthey tell us the nearest term opportunities will take a few months to get into humans but that's still pretty fast back to you. >> all right meg, we know they're working hard on it meg tirrell. let's get to bertha coombs at the nasdaq watching one medical today. >> hey, carl they priced at the bottom of the range at $14 but getting a very nice opening at $18 a share, which will give the primary care health services company a valuation somewhere close to $2 billion. this is a company that does primary care clinics it's really coordinated. it's a $199 membership fee for individuals. they have 6,000 san bernardino prize clients which foot the bill for their workers they try to coordinate care for them, provide access, same-day appointments and also 24/7 virtual care through mobile and desktop and telephone. it's a big debut for them on a day we're seeing health care down with everything else, but health technology today has outperformed the rest of the health care sector and this ipo here

not just for the potential funding sources even more helpful for small companies but we heard from regeneron it is helpful to know the right people and who to talk to to get things done and having the partnership to connect you within different organizations, public health agencies around the world so it's very important that everybody's working together and nih is giving guidance to companies, working with how to select the targets for the vaccines and so much collaboration going on between government and private industry on this. >> a huge evolution in communication since sars, mers and ebola and the coronavirus here thank you very much for that reporting. >> thank you. >>> coming up on the show, with many chinese cities essentially coming a screeching halt, the retail sector could see major supply chain disruptions we look at who could be the biggest impacted by the particular changes. >>> semiconductor stocks on pace for the worst performance since august will the disruption in chi pna t more pressure on that sector we'll explain. how's the it department liking the now platform? every ti

shares of regeneron, up more than 25% ith

the exception is regeneron, which is working on a potential drug but it closed down today about 1.7% the smaller micro cap names that are volatile during outbreak headlines though analysts say some of the moves may be exaggerated johnson & johnson is the world's largest health care company and has experience creating vaccines we talked with paul stofls about their previous work and what it suggests for this time around. >> we have done this in ebola, in six months from having a construct virus to scaling it up and bringing it to humans. with zika we have done it in 12 months where we did not have the virus and we had to start from scratch. here here in the same situation as zika. we have from a sequence which we now know. >> looking into whether approved drugs for hiv is helpful against the coronavirus. smaller bioteches are also in the hunt this morning we visited the labs of moderna which is working with the nih on a potential vaccine together they have selected the protein on the virus for the vaccine to target. moderna is working on producing enough to supply the nih to supply a

vac teen at nih and one by the company regeneron joo scary stuff and big story, meg thank you. >>> outbreak rattling investors around the globe asia markets tumbling overnight. check out casino stocks. las vegas sands, m elco selling off big properties in macao. there is clearly real fear surrounding the outbreak tim, what is your take on the market reaction. >> with that, any insensitivity -- there is sovly people sick around the world this is a big global health issue. but i can tell you from a market perspective and someone that was investing in emerging markets when sars was first diagnosed and became the epidemic people the thought was pandemic ultimate economic impact was zero short lived if anything. and i think the reaction today is one where people regret selling into this kind of weakness. >> tease that's fair enough. but wynn resorts for example look at the april 20th high. came in at 151 look where we topped out 151 wynn reports january 30th. with these headlines, my instinct is you have a bit of double top in the short-term and it sells off people aren't guying until you get th

regeneron, 1500 jobs, the largest project ever in the state of new york. willevelopment center retrain thousands of buffalo's inner-city youth for jobs. the largest expansion of upstate tourism, a new center state fair, new stadium to keep the mets in syracuse, historic modernization of the order facilities, we rebuilt the longest trail in the nation, c, theted hotel sarana premier destination in the north country, legoland is coming to the hud and valley -- the hudson valley, 1300 jobs. [applause] i love legoland. -- yes, kids, that is your next vacation. we are going to legoland. get ready. renewable program, we started the albany skyway, rebuilt jones beach, we have the nations largest offshore wind project, rebuilding roberta clemency state park, the largest land acquisition in the adirondacks in 100 years. the newest state park in brooklyn, the largest state park in new york city. 400 acres. bridge, i know, first new bridge and 50 years. the south bronx transformation at the sheridan expressway. hubs, all the new york city bridges and tunnels. we are

a different drug, from regeneron, brought the death rate down to 29%. >> i was at the origin of the discovery of the virus. i have also development of a molecule that can treat ebola patients. >> reporter: the treatment was a breakthrough. but with a third of the patients pill dying, the vaccine was critical; a way tect millions from being infected in the first place.s the vaccine rn in a post- 9/11 world. research targeted viruses, like ebola, that could be used in bioterrorist attacks. early research was led by's canaealth agency. but when ebola erupted in west africa, the vaccine sn't ready. the world health organization and government officials called on pharmaceutical maker merck. kennneth frazier is the c.e.o. >> it wasn't the typical situation where you're developing a vaccine from scratch. a lot of sentific work had gone on for a number of years and we were asd to come in and finish the research and the development and the formulation >> reporter: the merck vaccine was first tested at the very end of the west african outbreak. it was over 90% effective. in eastern congo, more than a q

. >> and i want to clarify, not a new high for regeneron and bristol, lilly, medtronic -- >> merck makingl >> really phoning it in the end of the show here >> too many things on my paper and i can't read any of it oh, well let's did fino final trades >> the bank earnings kick off next week and i think that the banks have underperformed. if you look at positioning and you look at sentiment, positioning right now is the most negative it has been in eight years and when you look at the discount relative to the s&p 500, it is trading at the most discounted level relative to the s&p 500 in about the same time frame. i like the banks because although i do think that this quarter is likely to be choppy, you still have a lot of restructuring, a lot of writeoffs that you may see which will impact fundamental earnings when you look forward into 2020, i do think particularly in the second half of the year that the outlook likes a little bit better names will continue to be compressed and margins will continue to be underpressure given the outlook for rates. that said we could start to see some earni

regeneron. largest biopharma ever in new york. will retrain thousands of buffalo's inner city youth for jobs. largest expansion of upstate tourism. a approximate new expo center at the state fair. new stadium to keep the mets in syracuse. new utica nexus center. historic modernization of the order facilities. we built the longest multiuse trail in the nation. we vane renovated hotel saranac. lego land coming to the hudson valley. 1,300 jobs. i love lego land. yes, kids, that is your next vacation. we're going to lego land. get ready. nation-leading renewable energy program. largest artificial reef expansion in history. we started the albany skyway. we rebuilt jones beach for the first time since it was built. we have the nation's largest offshore wind project. we're rebuilding roberto clemente state park. largest land acquisition in 100 years. newest state park in brooklyn. largest state park in new york city. the shirley chism park, 400 acres. the bridge. i know. first new bridge in 50 years. south bronx transformation at the she

companies line regeneron confirmed they are on work on a potential treatment for this virus. with ebola we got work within six months this will take time. >>> joining us now on the phone, dr. scott gotlieb former faa commissioner thank you for joining us first of all your again ral take on what we know about this virus and how concerned we should be >> it's concerning coronavirus generally isn't that virulent when you see a new virus starting to be spread in a human-to-human population you are concerned about it because people haven't been previously exposed to it. people can get quite ill coronavirus should be something that's self-limiting more serious in the young or old or infirmed but this is a new virus we don't have a lot of experience with. the question is there sustained human-to-human spread right now and has it achieved the sweet spot where it's virulent enough to cause significant illness but not so serious it doesn't achieve sustained spread because people are too sick to transmit. >> it's a virus that some way is similar to sars which takes us back 2002-2003 whe

she was able to track down that regeneron is working on a treatment for this similar to how they developed a treatment for ebola. earlier today, i spoke with the ceo of mederna they arepeutics. they are working on a vaccine. now there has been the first case of human-to-human transmitting they have to look at how this is transferred. what is interesting, they have developed a cancer vaccine they can develop and get into the patient in 40 days they are hoping to use that same technology to now do it for a contagious disease very interesting >> the flu vaccine the rhino virus, which is the common cold virus. >> the question is how quickly does it mute ate >> it doesn't look nearly as deadly as sars >> at this point >> you don't know how quickly this mutates >> i sat down with the president and discussed this and many other topics here we go it is great to see you, thank you for joining us again in davos. we've done this before >> that's right. >> before we get started, we'll talk about the economy and other things the cdc has identified a case of coronavirus in washington state. if you remem